LISATA THERAPEUTICS, INC.
LISATA THERAPEUTICS, INC. (LSTA): 4 pipeline candidates · 1 upcoming catalyst · ~13 mo cash runway · 3 clinical trials. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
13.0 months
D/E 0.31 · 0% dilution
Lead: Phase 2
4 candidates
1 upcoming, next in ~1293d
N/A
A transparent, data-derived signal for LISATA THERAPEUTICS, INC.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$31.4M
Cash
$13.1M
Quarterly Burn
$3.1M
Runway
13.0 mo
Revenue
$0
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (4 candidates)
| Drug | Phase |
|---|---|
| certepetide | Phase 2 |
| clbs16 | Phase 2 |
| folfox regimen | Phase 2 |
| lsta1 | Phase 2 |
Upcoming Catalysts (1)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
33
Total value held
$6.0M
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 543,630 | $2.7M |
| renaissance technologies llc | 131,715 | $660K |
| deltec asset management llc | 90,000 | $451K |
| geode capital management, llc | 70,887 | $355K |
| css llc/il | 61,898 | $310K |
| blackrock, inc. | 54,857 | $275K |
| penderfund capital management ltd. | 47,500 | $238K |
| vanguard fiduciary trust co | 34,917 | $175K |
| gts securities llc | 31,396 | $157K |
| state street corp | 25,348 | $127K |
Showing top 10 of 33 institutional holders of LISATA THERAPEUTICS, INC.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in LISATA THERAPEUTICS, INC.'s pipeline?
LISATA THERAPEUTICS, INC. (LSTA) has 4 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is LISATA THERAPEUTICS, INC.'s lead drug candidate?
LISATA THERAPEUTICS, INC.'s most advanced tracked candidate is certepetide (Phase 2) for Cholangiocarcinoma; Pancreas Cancer.
What is LISATA THERAPEUTICS, INC.'s next catalyst?
LISATA THERAPEUTICS, INC.'s next tracked catalyst is a Phase2_Start event — "Phase 2 Start: A Phase 1b/2a, Double-blind, Placebo-controlled, Three Arm, Randomized Study Evaluating a Single Int" — expected January 1, 2030.
What is LISATA THERAPEUTICS, INC.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, LISATA THERAPEUTICS, INC. has approximately 13.0 months of cash runway.
What is LISATA THERAPEUTICS, INC.'s market capitalization?
LISATA THERAPEUTICS, INC.'s market capitalization is approximately $31.4M.
Get the full picture on LISATA THERAPEUTICS, INC.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.